200 related articles for article (PubMed ID: 31764175)
1. Significance of alternative splicing in cancer cells.
Qi F; Li Y; Yang X; Wu YP; Lin LJ; Liu XM
Chin Med J (Engl); 2020 Jan; 133(2):221-228. PubMed ID: 31764175
[TBL] [Abstract][Full Text] [Related]
2. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
3. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
4. Splicing Regulators and Their Roles in Cancer Biology and Therapy.
da Silva MR; Moreira GA; Gonçalves da Silva RA; de Almeida Alves Barbosa É; Pais Siqueira R; Teixera RR; Almeida MR; Silva Júnior A; Fietto JL; Bressan GC
Biomed Res Int; 2015; 2015():150514. PubMed ID: 26273588
[TBL] [Abstract][Full Text] [Related]
5. From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.
Tian N; Li J; Shi J; Sui G
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257090
[TBL] [Abstract][Full Text] [Related]
6. The Functional Impact of Alternative Splicing in Cancer.
Climente-González H; Porta-Pardo E; Godzik A; Eyras E
Cell Rep; 2017 Aug; 20(9):2215-2226. PubMed ID: 28854369
[TBL] [Abstract][Full Text] [Related]
7. Unbalanced alternative splicing and its significance in cancer.
Venables JP
Bioessays; 2006 Apr; 28(4):378-86. PubMed ID: 16547952
[TBL] [Abstract][Full Text] [Related]
8. Alternative splicing and cancer: a systematic review.
Zhang Y; Qian J; Gu C; Yang Y
Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
[TBL] [Abstract][Full Text] [Related]
9. Regulation of alternative splicing of CD44 in cancer.
Prochazka L; Tesarik R; Turanek J
Cell Signal; 2014 Oct; 26(10):2234-9. PubMed ID: 25025570
[TBL] [Abstract][Full Text] [Related]
10. Human telomerase reverse transcriptase regulation by DNA methylation, transcription factor binding and alternative splicing (Review).
Avin BA; Umbricht CB; Zeiger MA
Int J Oncol; 2016 Dec; 49(6):2199-2205. PubMed ID: 27779655
[TBL] [Abstract][Full Text] [Related]
11. The alternative splicing side of cancer.
Biamonti G; Catillo M; Pignataro D; Montecucco A; Ghigna C
Semin Cell Dev Biol; 2014 Aug; 32():30-6. PubMed ID: 24657195
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of splicing factors and breast cancer development.
Silipo M; Gautrey H; Tyson-Capper A
J Mol Cell Biol; 2015 Oct; 7(5):388-401. PubMed ID: 25948865
[TBL] [Abstract][Full Text] [Related]
13. Aberrant alternative splicing in breast cancer.
Yang Q; Zhao J; Zhang W; Chen D; Wang Y
J Mol Cell Biol; 2019 Oct; 11(10):920-929. PubMed ID: 31065692
[TBL] [Abstract][Full Text] [Related]
14. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis.
Liu F; Dai M; Xu Q; Zhu X; Zhou Y; Jiang S; Wang Y; Ai Z; Ma L; Zhang Y; Hu L; Yang Q; Li J; Zhao S; Zhang Z; Teng Y
Oncogene; 2018 May; 37(18):2394-2409. PubMed ID: 29429992
[TBL] [Abstract][Full Text] [Related]
15. Splicing factors are differentially expressed in tumors.
Kirschbaum-Slager N; Lopes GM; Galante PA; Riggins GJ; de Souza SJ
Genet Mol Res; 2004 Dec; 3(4):512-20. PubMed ID: 15688317
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation.
Jia R; Ajiro M; Yu L; McCoy P; Zheng ZM
RNA; 2019 May; 25(5):630-644. PubMed ID: 30796096
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing in cancers: From aberrant regulation to new therapeutics.
Song X; Zeng Z; Wei H; Wang Z
Semin Cell Dev Biol; 2018 Mar; 75():13-22. PubMed ID: 28919308
[TBL] [Abstract][Full Text] [Related]
18. RNA splicing dysregulation and the hallmarks of cancer.
Bradley RK; Anczuków O
Nat Rev Cancer; 2023 Mar; 23(3):135-155. PubMed ID: 36627445
[TBL] [Abstract][Full Text] [Related]
19. Alternative splicing: an emerging topic in molecular and clinical oncology.
Pajares MJ; Ezponda T; Catena R; Calvo A; Pio R; Montuenga LM
Lancet Oncol; 2007 Apr; 8(4):349-57. PubMed ID: 17395108
[TBL] [Abstract][Full Text] [Related]
20. Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing pathway.
Lu GY; Liu ST; Huang SM; Chang YL; Lin WS
Biochimie; 2014 Nov; 106():131-9. PubMed ID: 25193633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
